BioLife Q4 preliminary revenue $32.7M, down 26% YoY; cell processing up 11% sequentially

BIOLIFE SOLUTIONS INC

2023-FY EPS reported -$1.52 revenue$143,271,000

Q4 2023 total preliminary unaudited revenue $32.7M, down 26% vs Q4 2022 ($44.3M).
Cell processing platform revenue $14.8M, down 27% YoY but up 11% sequentially from Q3 2023.
Full-year 2023 revenue $143.3M, down 11% from $161.8M in 2022.
Divestiture of freezer business progressing; expected to close in Q1 2024.
CEO cites 14 approved CGT therapies using BioLife products; 10 more potential by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOLIFE SOLUTIONS INC reported the fourth quarter of 2023 results: revenue $32.7 million.

Period: the fourth quarter of 2023
Revenue: $32.7 million
Result: preliminary results

Exact text from the filing

Preliminary and unaudited revenue for the fourth quarter of 2023 was $32.7 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOLIFE SOLUTIONS INC reported the full year 2023 results: revenue $143.3 million.

Period: the full year 2023
Revenue: $143.3 million
Result: preliminary results

Exact text from the filing

Preliminary and unaudited revenue for the full year 2023 was $143.3 million

View on SEC.gov

Browse all earnings releases →

BIOLIFE SOLUTIONS INC filing history →

Source: SEC EDGAR

accession 0001628280-24-000776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.